<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244842</url>
  </required_header>
  <id_info>
    <org_study_id>ISA04-03</org_study_id>
    <nct_id>NCT00244842</nct_id>
  </id_info>
  <brief_title>Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis</brief_title>
  <acronym>SPIRIT</acronym>
  <official_title>A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which dose of voclosporin is effective in the
      treatment of plaque psoriasis compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic skin condition that can have a significant impact on patient's
      physical and mental well being. The most common form of psoriasis is plaque psoriasis.
      Targeted treatments in psoriasis have been reported recently, yet cyclosporine, a calcineurin
      inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin
      represents the possibility of a calcineurin inhibitor which is not only as efficacious as
      cyclosporine A, but also has an improved toxicity profile.

      Comparison(s): Voclosporin at 3 dose levels (0.2, 0.3, and 0.4 mg/kg twice a day)compared to
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving a PASI-75 at 12 weeks at each of the 3 dose levels of voclosporin.</measure>
    <time_frame>Twelve Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of voclosporin.</measure>
    <time_frame>Twelve and twenty four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacokinetics and pharmacodynamics of voclosporin after chronic dosing in a subset of subjects.</measure>
    <time_frame>Twelve and twenty four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of voclosporin on subject quality of life</measure>
    <time_frame>Twelve and twenty four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voclosporin</intervention_name>
    <description>voclosporin 0.2, 0.3, or 0.4 mg/kg po BID</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plaque psoriasis ≥ 6 months prior to screening.

          -  Diagnosis of stable, plaque psoriasis; i.e. psoriasis must not be spontaneously
             improving or worsening in the 4 weeks prior to the screening visit.

          -  Plaque psoriasis involving ≥10% of the body surface area (BSA) at screening and prior
             to randomization at the day 0 visit.

          -  PASI score ≥10 at screening and prior to randomization at the day 0 visit.

          -  Not pregnant or nursing or planning to become pregnant during the course of the study.

          -  Sexually active women of childbearing potential or less than 1 year post-menopausal
             and sexually active men who are not surgically sterile must use a reliable form of
             birth control during study treatment and for at least 3 months after the last dose of
             study drug. Surgically sterile females are not considered to be of childbearing
             potential. Reliable forms of birth control include oral or depot contraceptives, and
             double-barrier methods.

          -  Written informed consent prior to washout and screening procedures.

          -  Able to keep study appointments and cooperate with all study requirements, in the
             opinion of the investigator.

        Exclusion Criteria:

          -  Has generalized erythrodermic, guttate, or pustular psoriasis.

          -  Have other dermatoses that would interfere with the evaluation of psoriasis, at the
             discretion of the investigator.

          -  A current malignancy or history of malignancy within 5 years or a history of lymphoma
             at any time. Subjects can be enrolled with a history of squamous or basal cell
             carcinoma that has been surgically excised or removed with curettage and
             electrodesiccation.

          -  Has current, uncontrolled bacterial, viral, or fungal infections that require
             intravenous antibiotics or antifungals or had had such infections within 60 days prior
             to screening.

          -  A history of streptococcal infection that required oral antibiotics within 30 days
             prior to screening.

          -  A known history of tuberculosis.

          -  Serologic evidence or known latent human immunodeficiency virus (HIV), hepatitis B
             (HBV) or hepatitis C (HCV) virus.

          -  Uncontrolled hypertension as defined by systolic blood pressure ≥150 mm Hg or
             diastolic blood pressure ≥ 90 mm Hg.

          -  MDRD GFR ≤ 60 ml/min.

          -  Variation between the screening and Visit 1 GFR ≥30%.

          -  Alanine transaminase, aspartate transaminase, or gamma-glutamyl transferase ≥ 3x upper
             limit of normal (ULN).

          -  White blood cell count ≤ 2.8 x 109/L.

          -  Triglycerides ≥ 3x ULN.

          -  Requires the following prohibited medications or treatments during the washout or
             treatment period: drugs potentiating the nephrotoxicity of voclosporin such as NSAID's
             or ACE inhibitors, drugs interfering with its pharmacokinetics; drugs considered to
             contribute to psoriasis flare; or, systemic and topical psoriasis medication
             (including psoralen/ultraviolet A light treatment) that may interfere with assessment
             of study drug efficacy.

          -  Has used any investigational drug or device within 28 days or 5 half lives (whichever
             is longer) prior to the screening visit.

          -  Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3
             months of the start of treatment. Biological agents include any virus, therapeutic
             serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment,
             or cure of diseases or injuries of man.

          -  Previous exposure to voclosporin.

          -  A history of clinically defined allergy to cyclosporine or any of the constituents of
             the voclosporin formulation (vitamin E, medium chain triglyceride oil, Tween 40,
             ethanol).

          -  A history of alcoholism or drug addiction within 1 year prior to study entry.

          -  Weighs &lt;45 kg (99 lbs) or &gt; 140 kg (308 lbs).

          -  A history of disease, including mental/emotional disorder that would interfere with
             the subject's participation in the study, or that might cause the administration of
             ISA247 to pose a significant risk to the subject, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bissonnette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innovaderm Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Langley, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Canada Cutaneous Research Associates Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Lauzon, PhD MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Canada Dermatology Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Papp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Probity Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Shear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ventana Clinical Research Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site`</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5J 3S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5J 3S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4F8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Maple</city>
        <state>Ontario</state>
        <zip>L4K 5V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 6P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7G 2C0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Ste. Foy</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004 Sep 15;78(5):681-5.</citation>
    <PMID>15371668</PMID>
  </reference>
  <reference>
    <citation>Stalder M, Bîrsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003 Dec;22(12):1343-52.</citation>
    <PMID>14672749</PMID>
  </reference>
  <reference>
    <citation>Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001 Feb;20(2):161.</citation>
    <PMID>11250240</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Huizinga</name_title>
    <organization>Isotechnika Inc</organization>
  </responsible_party>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Adult</keyword>
  <keyword>Chronic Disease</keyword>
  <keyword>Dermatologic Agents</keyword>
  <keyword>Female</keyword>
  <keyword>Humans</keyword>
  <keyword>Male</keyword>
  <keyword>Middle Aged</keyword>
  <keyword>Severity of Illness Index</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Double-Blind Method</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 12, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

